A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: RC48-ADC|DRUG: Paclitaxel Injection|DRUG: Docetaxel Injection|DRUG: Vinorelbine Tartrate Injection|DRUG: Capecitabine Tablets
Sponsor: RemeGen Co., Ltd.